MedCap AB (publ) (MCAP.ST) fair value

ACCE thesis

MedCap AB is a Swedish medical devices company whose main revenue comes from surgical and clinical products sold into hospitals, and the financial profile reflects a business that is growing faster than most of its sector while keeping a 59.4% gross margin. Revenue is growing 16.2% and return on equity sits at 16.4%, so growth is not being bought with balance-sheet strain. The obvious question is the valuation: the trailing P/E of 34.1 falls to a forward P/E of 107.7, which implies consensus earnings fall sharply or the forward figure is distorted by one-off items, and that gap needs reconciling before anyone reads it as a signal. A 14.6% operating margin against a 59.4% gross margin says most of the gross profit is consumed by selling and overhead, so operating leverage is the thing to test in the next few reports. This is worth a deeper look for the margin-expansion case and the earnings-revision question, not on the strength of the headline numbers alone.